Combined Positron Emission Tomography and Cerenkov Luminescence Imaging of Sentinel Lymph Nodes Using PEGylated Radionuclide-Embedded Gold Nanoparticles
New imaging probes with high sensitivity and stability are urgently needed to accurately detect sentinel lymph nodes (SLNs) for successful cancer diagnosis. Herein, the use of highly sensitive and stable PEGylated radionuclide‐embedded gold nanoparticles (PEG‐RIe‐AuNPs) is reported for the detection...
Saved in:
Published in | Small (Weinheim an der Bergstrasse, Germany) Vol. 12; no. 35; pp. 4894 - 4901 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Blackwell Publishing Ltd
01.09.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | New imaging probes with high sensitivity and stability are urgently needed to accurately detect sentinel lymph nodes (SLNs) for successful cancer diagnosis. Herein, the use of highly sensitive and stable PEGylated radionuclide‐embedded gold nanoparticles (PEG‐RIe‐AuNPs) is reported for the detection of SLNs by combined positron emission tomography and Cerenkov luminescence imaging (PET/CLI). PEG‐RIe‐AuNPs show high sensitivity and stability both in vitro and in vivo, and are not toxic to normal ovarian and immune cells. In vivo PET/CLI imaging clearly reveals SLNs as early as 1 h post PEG‐RIe‐AuNP‐injection, with peak signals achieved at 6 h postinjection, which is consistent with the biodistribution results. Taken together, the data provide strong evidence that PEG‐RIe‐AuNPs are promising as potential lymphatic tracers in biomedical imaging for pre and intraoperative surgical guidance.
PEGylated radionuclide‐embedded gold nanoparticles with excellent sensitivity and stability as new multimodal imaging platform are successfully applied to detect sentinel lymph nodes by the use of combined positron emission tomography and Cerenkov luminescence imaging, suggesting the strong feasibility of PEG‐RIe‐AuNPs as potential lymphatic tracers in the clinical setting. |
---|---|
Bibliography: | ark:/67375/WNG-Z9Z42DRX-C istex:1F6C168CC2637B6143F54A74A48A94A2E1EA85DF ArticleID:SMLL201601721 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1613-6810 1613-6829 |
DOI: | 10.1002/smll.201601721 |